Trial reportAnnals of neurology2019
The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial.
Trial report in Annals of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06606574 (PREDICT-ITB), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PREDICT-ITB: Predicting Response in Children With Dystonic Cerebral Palsy to Intrathecal Baclofen
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.Developmental medicine and child neurology · 2021Pooled it
- Instrumented assessment of motor function in dyskinetic cerebral palsy: a systematic review.Journal of neuroengineering and rehabilitation · 2020Pooled it
- Use of the Dyskinesia Impairment Scale in non-ambulatory dyskinetic cerebral palsy.Developmental medicine and child neurology · 2020Trial
- Article
- 2024 Japan Society for Stereotactic and Functional Neurosurgery Guidelines for Stereotactic and Functional Neurosurgery.Neurologia medico-chirurgica · 2026Article
- Neurosurgery to restore function in cerebral palsy: current practice and emerging therapies.Frontiers in rehabilitation sciences · 2026Review
- Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Potentially Life-Threatening Interaction between Opioids and Intrathecal Baclofen in Individuals with a Childhood-Onset Neurological Disorder: A Case Series and Review of the Literature.Neuropediatrics · 2024Review
- Les soins aux enfants et aux adolescents ayant la paralysie cérébrale (aux niveaux III à V du GMFCS).Paediatrics & child health · 2024Review
- Care for children and youth with cerebral palsy (GMFCS levels III to V).Paediatrics & child health · 2024Review
- Surgical treatment options for spasticity in children and adolescents with hereditary spastic paraplegia.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Spasticity and movement disorders in cerebral palsy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Intrathecal baclofen as an effective treatment for generalized dystonia in Wilson's disease.European journal of physical and rehabilitation medicine · 2023Article
- Elective and Emergency Deep Brain Stimulation in Refractory Pediatric Monogenetic Movement Disorders Presenting with Dystonia: Current Practice Illustrated by Two Cases.Neuropediatrics · 2023Review
- Towards automated video-based assessment of dystonia in dyskinetic cerebral palsy: A novel approach using markerless motion tracking and machine learning.Frontiers in robotics and AI · 2023Article
- Home-Based Measurements of Dystonia in Cerebral Palsy Using Smartphone-Coupled Inertial Sensor Technology and Machine Learning: A Proof-of-Concept Study.Sensors (Basel, Switzerland) · 2022Article
- The Effects of Preterm Birth on Musculoskeletal Health-Related Disorders.Journal of clinical medicine · 2021Review
- Intrathecal baclofen therapy for Lesch-Nyhan disease: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.Journal of psychopharmacology (Oxford, England) · 2021Review
- Musculoskeletal Pain Outcomes Pre- and Post Intrathecal Baclofen Pump Implant in Children With Cerebral Palsy: A Prospective Cohort Study.Archives of rehabilitation research and clinical translation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveIntrathecal baclofen treatment is used for the treatment of dystonia in patients with severe dyskinetic cerebral palsy; however, the current level of evidence for the effect is low. The primary aim of this study was to provide evidence for the effect of intrathecal baclofen treatment on individual goals in patients with severe dyskinetic cerebral palsy.
methodsThis multicenter, randomized, double-blind, placebo-controlled trial was performed at 2 university medical centers in the Netherlands. Patients with severe dyskinetic cerebral palsy (Gross Motor Functioning Classification System level IV-V) aged 4 to 24 years who were eligible for intrathecal baclofen were included. Patients were assigned by block randomization (2:2) for treatment with intrathecal baclofen or placebo for 3 months via an implanted microinfusion pump. The primary outcome was goal attainment scaling of individual treatment goals (GAS T score). A linear regression model was used for statistical analysis with study site as a covariate. Safety analyses were done for number and type of (serious) adverse events.
resultsThirty-six patients were recruited from January 1, 2013, to March 31, 2018. Data for final analysis were available for 17 patients in the intrathecal baclofen group and 16 in the placebo group. Mean (standard deviation) GAS T score at 3 months was 38.9 (13.2) for intrathecal baclofen and 21.0 (4.6) for placebo (regression coefficient = 17.8, 95% confidence interval = 10.4-25.0, p < 0.001). Number and types of (serious) adverse events were similar between groups.
interpretationIntrathecal baclofen treatment is superior to placebo in achieving treatment goals in patients with severe dyskinetic cerebral palsy. ANN NEUROL 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.